Moderna’s Future: Balancing Growth Potential and Uncertainty with a Hold Rating

Moderna (MRNA) has received a new Hold rating, initiated by Jefferies analyst, Andrew Tsai.

Andrew Tsai has given his Hold rating due to a combination of factors that reflect both potential and uncertainty in Moderna’s future performance. One key consideration is the anticipated stabilization of COVID-19 sales by 2026, although the long-term outlook remains uncertain. Tsai notes that while there is potential for growth in non-COVID revenue streams such as flu and RSV vaccines, these are not expected to significantly impact sales until 2027-2028.
Additionally, Tsai points out that Moderna’s path to achieving cash breakeven by 2028 is unclear, as it relies on consistent year-over-year revenue growth and faster expense reductions than currently projected by management. The analyst also highlights the potential for new product approvals in the coming years, which could contribute to revenue but are not expected to provide immediate financial traction. Given these factors, Tsai maintains a cautious stance with a Hold rating, reflecting both the opportunities and risks associated with Moderna’s stock.

In another report released on December 9, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $29.00 price target.